A Polymorphism Cluster at the 2q12 locus May Predict Response to Piromelatine in Patients with Mild Alzheimer’s Disease

Keyphrases

• Polymorphism 100%
• Response Predictors 100%
• Mild Alzheimer's Disease 100%
• Piromelatine 100%
• Placebo 36%
• Neuropsychological Battery 27%
• Computerized Cognitive Assessment 27%
• Pittsburgh Sleep Quality Index 27%
• Genome-wide Association 27%
• Single nucleotide Polymorphism 18%
• Non-carriers 18%
• Alzheimer's Disease 9%
• Whole Genome 9%
• Lymphocytes 9%
• Non-responders 9%
• Receptor Agonist 9%
• Genetic Markers 9%
• Whole Exome Sequencing 9%
• Outpatient Clinic 9%
• Melatonin 9%
• Safety Concerns 9%
• Baseline Characteristics 9%
• Change from Baseline 9%
• Informed Consent 9%
• Randomized Placebo-controlled Trial 9%
• Treatment Response 9%
• Alzheimer's Disease Clinical Trials 9%
• Serotonin 5-HT 9%
• Early Alzheimer's Disease 9%
• 5-HT1A 9%
• Mild Dementia 9%
• Dose-ranging Study 9%
• Cochran-Armitage Trend Test 9%
• Baseline Response 9%
• Design Variants 9%
• Allelic Test 9%
• Variant Genotyping 9%

Biochemistry, Genetics and Molecular Biology

• Sleep Quality 100%
• Genotyping 66%
• Single-Nucleotide Polymorphism 66%
• Exome Sequencing 33%
• Cohort Study 33%
• Genetic Marker 33%
• Alzheimer's Disease Clinical Trial 33%
• Receptor Agonists 33%
• Lymphocyte 33%
• Serotonin 33%
• Melatonin 33%